Pegfilgrastim primary prophylaxis vs. current practice neutropenia management in elderly breast cancer patients receiving chemotherapy.


Journal Article (Review)

We investigated the incidences of febrile neutropenia (FN) and related complications in elderly (> or =65 years) breast cancer patients receiving chemotherapy supported by pegfilgrastim primary prophylaxis (PP; n=150) or current practice (CP) neutropenia management (n=104) in a subanalysis of NeuCuP (Neulasta) vs. current practice neutropenia management). Studies involving regimens with moderately high to high (> or =15%) FN risk were identified by literature review, and individual patient data were integrated for analysis. FN incidence was 6% (95% CI: 2, 10%) in the PP group and 24% (95% CI: 16, 32%) in the CP group. In cycle 1, incidences were 3 and 15%, respectively. FN-related hospitalisation incidence was 5% (PP group) and 15% (CP group), while dose reductions (>/=15%) occurred in 15 and 29% of patients. Pegfilgrastim provided effective PP in elderly patients, a population who may be vulnerable to chemotherapy-related FN and for whom current practice may not provide adequate protection.

Full Text

Duke Authors

Cited Authors

  • Aapro, M; Schwenkglenks, M; Lyman, GH; Lopez Pousa, A; Lawrinson, S; Skacel, T; Bacon, P; von Minckwitz, G

Published Date

  • June 2010

Published In

Volume / Issue

  • 74 / 3

Start / End Page

  • 203 - 210

PubMed ID

  • 19748281

Pubmed Central ID

  • 19748281

Electronic International Standard Serial Number (EISSN)

  • 1879-0461

Digital Object Identifier (DOI)

  • 10.1016/j.critrevonc.2009.06.004


  • eng

Conference Location

  • Netherlands